A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2 [3]

AIDS

Volumn 20, Issue 11, 2006, Pages 1564-1565

  Pao, David ^a   Smit, Erasmus ^b   Imami, Nesrina ^c   Fisher, Martin ^a  

^a UK   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACCURACY; ADULT; BLOOD ANALYSIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DISEASE COURSE; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SYPHILIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MALE; VIRAL LOAD;

EID: 33746216570     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000237378.69433.6b     Document Type: Letter

References (11)

1. Wilson JD, Imami N, Watkins A, Gill J, Hay P, Cazzard B, et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000; 182:792-798.
2. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76:9011-9023.
3. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-878.
4. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med 2001; 134:978-996.
5. CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
6. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031-1038.
7. Leigh-Brown A. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686.
8. Johnson JA, Li, JF, Brant A, Bennet D, Cong M, Spira T, et al. Multi-drug resistant HIV-1 are transmitted more frequently than current estimates. 14th International HIV Drug Resistance Workshop, Canada 2005. Abstract 111.
9. Van de Vijver DAMC, Wensig AMJ, Åsjö B, Bruckova M, Bruun Jorgensen L, Horban A, et al. Selective transmission of drug resistance mutations. 14th International HIV Drug Resistance workshop, Canada 2005. Abstract 113.
10. Deeks SG. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest 2004; 113:808-810.
11. Youle M, Emery S, Fisher M, Nelson M, Tavel JA, Fosdick L, et al. A randomised, controlled pilot trial of subcutaneous intermittent interleukin-2 without concurrent antiretroviral therapy in subjects infected with the human immunodeficiency virus. PLoS Clinical Trials 1:e3. DO*I:10.1371/journal. pctr.0010003.